There have been many stocks which have not performed particularly well over the course of the past week and one of those is that of Skye Bioscience Inc (OTCMKTS:SKYE). The company, which is involved in the development of proprietary CBD based molecular for treating diseases with considerable unmet need, has seen its stock decline by as much as 17% over the past week.
Yesterday, the company was in the news after it announced that it had further strengthened its management team with two key appointments. One of those was a new Head of Regulatory Affairs & Quality Assurance in the form of Rhea Williams and the other was Varun Khurana, who was made the Senior Director of Research and Development.
Those are two highly critical roles and could have a significant impact on the long term prospects of Skye. Williams is a highly experience operators who has worked for a quarter of a century in roles related to quality assurance, medicine development and regulatory affairs. On the other hand, Varun Khurana is also an experienced had and has been working in the formulation and pre-forumulation development space for the past seven years.
